Fast path: latest quarter results by ticker or company name

Reported Q: Q4 2024 Rev YoY: -2.8% EPS YoY: +130.6% Move: -0.48%

Safilo Group SpA

0NJ5.L

€1.767 -0.48%

Exchange LSE Sector Healthcare Industry Medical Instruments Supplies

Q4 2024

Published: Dec 31, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for 0NJ5.L

Reported

Report Date

Dec 31, 2024

Quarter Q4 2024

Revenue

461.26M

YoY: -2.8%

EPS

0.01

YoY: +130.6%

Market Move

-0.48%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $461.26M down 2.8% year-over-year
EPS of $0.01 increased by 130.6% from previous year
Gross margin of 56.0%
Net income of 4.69M
"" -

0NJ5.L

Company 0NJ5.L

Period Q4 2024

Currency EUR

Report Type Quarterly Earnings

Generated Apr 14, 2026

Swipe to view all report sections

Executive Summary

Safilo Group reported a strong Q4 2024 despite a negative year-over-year revenue trend, delivering a pronounced sequential bounce with revenue of EUR461.3 million, up 100% QoQ from Q3 2024. The quarter achieved a gross profit of EUR258.16 million and a gross margin of 55.97%, reflecting a favorable product mix and pricing discipline, even as margins moderated modestly versus Q3 2024. Operating income reached EUR11.26 million, up 211% YoY and 155% QoQ, with EBITDA of EUR36.83 million and EBITDA margin of 7.98%. Net income stood at EUR4.69 million and earnings per share (diluted) at EUR0.0116, underscoring a meaningful improvement in profitability from the prior year period.

Key Performance Indicators

Revenue

Decreasing

461.26M

QoQ: 100.00% | YoY: -2.81%

Gross Profit

Increasing

258.16M

55.97% margin

QoQ: 88.71% | YoY: 6.25%

Operating Income

Increasing

11.26M

QoQ: 155.30% | YoY: 211.04%

Net Income

Increasing

4.69M

QoQ: 100.00% | YoY: 129.89%

EPS

Increasing

0.01

QoQ: 103.51% | YoY: 130.61%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: EUR461.262m; YoY -2.81%; QoQ +100.00%. Gross Profit: EUR258.161m; YoY +6.25%; QoQ +88.71%. Operating Income: EUR11.255m; YoY +211.04%; QoQ +155.30%. EBITDA: EUR36.827m; EBITDA Margin: 7.98%. Net Income: EUR4.69m; YoY +129.89%; QoQ +100.00%. EPS (Diluted): EUR0.0116; YoY +130.61%; QoQ +103.51%. Gross Margin: 55.97%; Operating Margin: 2.44%; Net Margin: 1.02%. Cash Flow: Operating Cash Flow EUR48.871m; Free Cash Flow EUR42.563m; Capex EUR6.308m. Balance Sheet health: Total Assets EUR842.339m; Total Liabilities EUR414.878m; Equity EUR413.070m. Liquidity: Current Ratio 1.93; Quick Ratio 1.17; Cash Ratio 0.17. Leverage: Total Debt EUR130.1m; Net Debt EUR82.679m; Debt/Equity 0.315. Working capital metrics: DSO 46.25 days; DIO 93.13 days; DPO 73.23 days; CCC 139.38 days.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	461.26M	-2.81%	100.00%
Gross Profit	258.16M	6.25%	88.71%
Operating Income	11.26M	211.04%	155.30%
Net Income	4.69M	129.89%	100.00%
EPS	0.01	130.61%	103.51%

Key Financial Ratios

Gross Profit Margin

Good

56.00%

Gross profit margin is healthy and competitive within industry standards

Operating Profit Margin

Weak

2.44%

Operating margin is below industry norms, profitability concerns

Net Profit Margin

Weak

1.02%

Net profit margin is below industry norms, profitability concerns

Return on Assets

Weak

0.56%

Return on assets suggests inefficient capital allocation

Return on Equity

Weak

1.14%

Return on equity suggests inefficient capital allocation

Current Ratio

Healthy

1.93

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

Moderate

0.32

Debt-to-equity indicates balanced capital structure with manageable debt

P/E Ratio

Fair Value

20.03x

P/E ratio in line with market averages

Price to Book

Undervalued

0.91x

Trading below book value, potential value opportunity or distressed

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q4 2025	445.75	0.02	+93.3%	View
Q2 2025	268.81	0.05	+133.1%	View
Q1 2025	268.81	0.05	+1.1%	View
Q4 2024	461.26	0.01	-2.8%	View
Q3 2024	230.63	0.01	-2.8%	View

0NJ5.L

Safilo Group SpA

Q4 2025 Report

Safilo Group SpA (0NJ5.L) QQ4 2025 Results Analysis – Resilient Gross Margin in a Soft Quarter with Solid Cash Generation...

Read full report

0NJ5.L

Safilo Group SpA

Q2 2025 Report

Safilo Group S.p.A. QQ2 2025 Results — Healthcare (Medical - Instruments & Supplies): Robust Revenue Growth, Margin Resilience and Prudent Balance S...

Read full report

0NJ5.L

Safilo Group SpA

Q1 2025 Report

Safilo Group S.p.A. QQ1 2025 Results: Revenue EUR 268.8m, Margin Resilience Across a Seasonally Tough Quarter...

Read full report

0NJ5.L

Safilo Group SpA

Q3 2024 Report

Safilo Group S.p.A. (0NJ5.L) Q3 2024 Results - Modest Margin Resilience Amid Sharp QoQ Revenue Contraction in Healthcare Eyewear...

Read full report

Safilo Group SpA (0NJ5.L) Q4 2024 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Historical Earnings Comparison

More 0NJ5.L Quarterly Reports

0NJ5.L

0NJ5.L

0NJ5.L

0NJ5.L

Related Financial Data

Sector Analysis: Healthcare

0NJ5.L Full Profile

0NJ5.L Financial Statements

Earnings Calendar